Manhattan Scients Current Valuation vs. Total Debt
Manhattan Scients Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Manhattan Scients's current stock value. Our valuation model uses many indicators to compare Manhattan Scients value to that of its competitors to determine the firm's financial worth. Manhattan Scients is regarded second in current valuation category among its peers. It is rated below average in total debt category among its peers making up about 0.03 of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Manhattan Scients is roughly 30.25 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Manhattan Scients by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Manhattan Scients' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Manhattan Current Valuation vs. Competition
Manhattan Scients is regarded second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 38.83 Million. Manhattan Scients retains roughly 4.33 Million in current valuation claiming about 11% of equities under Health Care industry.
Manhattan Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Manhattan Scients |
| = | 4.33 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Manhattan Scients |
| = | 143 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Manhattan Total Debt vs Competition
Manhattan Scients is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 18.79 Million. Manhattan Scients maintains roughly 143,000 in total debt contributing less than 1% to equities under Health Care industry.
Manhattan Scients Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Manhattan Scients, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Manhattan Scients will eventually generate negative long term returns. The profitability progress is the general direction of Manhattan Scients' change in net profit over the period of time. It can combine multiple indicators of Manhattan Scients, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Manhattan Scientifics, Inc., a technology incubator, engages in the development and commercialization of life-enhancing technologies in the United States. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York. Manhattan Scients operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 1 people.
Manhattan Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Manhattan Scients. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Manhattan Scients position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Manhattan Scients' important profitability drivers and their relationship over time.
Manhattan Scients Earnings per Share Projection vs Actual
Use Manhattan Scients in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Manhattan Scients position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Manhattan Scients will appreciate offsetting losses from the drop in the long position's value.Manhattan Scients Pair Trading
Manhattan Scients Pair Trading Analysis
The ability to find closely correlated positions to Manhattan Scients could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Manhattan Scients when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Manhattan Scients - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Manhattan Scients to buy it.
The correlation of Manhattan Scients is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Manhattan Scients moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Manhattan Scients moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Manhattan Scients can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Manhattan Scients position
In addition to having Manhattan Scients in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Manhattan Pink Sheet Analysis
When running Manhattan Scients' price analysis, check to measure Manhattan Scients' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Manhattan Scients is operating at the current time. Most of Manhattan Scients' value examination focuses on studying past and present price action to predict the probability of Manhattan Scients' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Manhattan Scients' price. Additionally, you may evaluate how the addition of Manhattan Scients to your portfolios can decrease your overall portfolio volatility.